### **AMENDMENTS TO THE CLAIMS**

The following listing of claims replaces all prior listings of claims presented in the application.

## **Claims**

1. (Currently amended) Compound of the formula

in which

A represents a radical

in which,

R<sup>7</sup> represents hydrogen, halogen, cyano, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, <u>or</u> phenyl or 5 or 6 membered heteroaryl,

where alkyl, cycloalkyl, <u>or</u> phenyl <del>or 5 or 6 membered heteroaryl</del> may be substituted by amino, hydroxyl, halogen,  $(C_1-C_3)$ -alkyl,  $(C_1-C_3)$ -alkoxy or  $(C_1-C_6)$ -alkylamino,

and

- \* represents the point of attachment to Y,
- Y represents O or NH,

R<sup>1</sup> and R<sup>2</sup> independently of one another represent hydrogen, halogen, cyano or (C<sub>1</sub>-C<sub>3</sub>)-alkyl,

R<sup>3</sup> and R<sup>4</sup> independently of one another represent hydrogen, fluorine, chlorine or methyl,

- R<sup>5</sup> represents hydrogen or (C<sub>1</sub>-C<sub>6</sub>)-alkyl,
- R<sup>6</sup> represents a radical selected from the group consisting of:

(C<sub>1</sub>-C<sub>6</sub>)-alkyl which is substituted by amino, hydroxyl,  $(C_1$ -C<sub>6</sub>)-alkoxy,  $(C_1$ -C<sub>6</sub>)-alkylamino, cyclohexylamino or piperidinyl  $(C_3$ -C<sub>8</sub>) cycloalkylamino,  $(C_4$ -C<sub>6</sub>) alkylcarbonylamino,  $(C_4$ -C<sub>6</sub>) alkoxycarbonyl,  $(C_3$ -C<sub>8</sub>) cycloalkyl,  $(C_6$ -C<sub>10</sub>) aryl, 5 to 10 membered heteroaryl or 5 to 10 membered heterocyclyl,

where alkylamino <u>or cyclohexylamino</u>, <u>eyeloalkylamino or aryl</u> for their part may be substituted by <del>amino</del>, hydroxyl <u>or phenyl</u>, halogen,  $(C_1 - C_6)$  alkylamino or  $(C_6 - C_{10})$  aryl,

Docket No.: BHC 031069 PCT-US

(C<sub>1</sub>-C<sub>6</sub>)-alkoxy which may be substituted by amino, hydroxyl or (C<sub>1</sub>-C<sub>6</sub>)-alkylamino, dimethylaminoethylamino,

cyclopentyl, piperazinyl, piperidinyl, pyrrolidinyl, piperidinyloxy or pyrrolidinyloxy (C<sub>3</sub>-C<sub>4</sub>) cycloalkyl, 5 to 10 membered heterocyclyl or 5 to 10 membered heterocyclyloxy,

where cyclopentyl, piperazinyl, piperidinyl, pyrrolidinyl, piperidinyloxy or pyrrolidinyloxy cycloalkyl, heterocyclyl or heterocyclyloxy may be substituted by amino, hydroxyl,  $(C_1-C_3[[_6]])$ -alkyl,  $(C_1-C_6)$  alkylamino, oxo or benzyloxy,

and phenyl or thienyl (C<sub>6</sub> C<sub>10</sub>) aryl or 5 to 10 membered heteroaryl,

where <u>phenyl</u> or <u>thienyl</u> aryl or <u>heteroaryl</u> may be substituted by <del>amino,</del> hydroxyl, halogen, eyano,  $(C_1-C_6)$ -alkyl[[,]] which for its part may be substituted by amino or  $(C_1-C_6)$ -alkylamino,  $(C_1-C_6)$  alkoxy,  $(C_1-C_6)$  alkylamino or  $(C_1-C_6)$ -alkoxyearbonyl,

4

Docket No.: BHC 031069 PCT-US

and its salts, hydrates, hydrates of the salts and solvates.

2. (Currently amended) Compound of the formula (I) according to Claim 1,

in which

A represents a radical

in which

R<sup>7</sup> represents hydrogen, chlorine or methyl,

and

- \* represents the point of attachment to Y,
- Y represents O,

R<sup>1</sup> and R<sup>2</sup> independently of one another represent hydrogen, fluorine or chlorine,

R<sup>3</sup> and R<sup>4</sup> independently of one another represent hydrogen or fluorine,

- R<sup>5</sup> represents hydrogen,
- R<sup>6</sup> represents a radical selected from the group consisting of:

(C<sub>1</sub>-C<sub>6</sub>)-alkyl which is substituted by amino, hydroxyl, (C<sub>4</sub>-C<sub>6</sub>) alkoxy, (C<sub>4</sub>-C<sub>6</sub>) alkylthio, (C<sub>1</sub>-C<sub>6</sub>)-alkylamino, cyclohexylamino or piperidinyl (C<sub>5</sub>-C<sub>6</sub>) cycloalkylamino, (C<sub>4</sub>-C<sub>6</sub>) alkylcarbonylamino, (C<sub>4</sub>-C<sub>6</sub>) alkoxycarbonyl, phenyl, 5 or 6 membered heterocyclyl,

where alkylamino[[,]] or cycloalkylamino or phenyl for their part may be substituted by hydroxyl, halogen,  $(C_1-C_2)$  alkoxy,  $(C_1-C_2)$  alkylamino or

#### phenyl,

 $(C_1-C_6)$ -alkoxy which may be substituted by amino or  $(C_1-C_6)$ -alkylamino,

cyclopentyl, <u>piperazinyl</u>, <u>piperidinyl</u>, <u>pyrrolidinyl</u>, <u>piperidinyloxy</u> or <u>pyrrolidinyloxy</u> eyelohexyl, 5 or 6 membered heterocyclyl or 5 or 6 membered heterocyclyloxy</u>,

where cyclopentyl, <u>piperazinyl</u>, <u>piperidinyl</u>, <u>pyrrolidinyl</u>, <u>piperidinyloxy</u> or <u>pyrrolidinyloxy</u> eyclohexyl, heterocyclyl or heterocyclyloxy may be substituted by amino, hydroxyl,  $(C_1-C_3)$ -alkyl, oxo or benzyloxy,

Docket No.: BHC 031069 PCT-US

and phenyl[[,]] or thienyl, furyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl or pyridazinyl,

where phenyl[[,]] <u>or</u> thienyl<del>, furyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl or pyridazinyl</del> may be substituted by <del>amino, hydroxyl, halogen, cyano,</del>  $(C_1-C_3)$ -alkyl[[,]] which for its part may be substituted by amino or  $(C_1-C_6)$ -alkylamino,  $(C_4-C_2)$ -alkoxy or  $(C_4-C_2)$ -alkoxycarbonyl,

and its salts, hydrates, hydrates of the salts and solvates.

3. (Currently amended) Compound of the formula (I) according to Claim 1,

in which

A represents a radical

in which

R<sup>7</sup> represents hydrogen, chlorine or methyl

and

\* represents the point of attachment to Y,

Y represents O,

R<sup>1</sup> and R<sup>2</sup> independently of one another represent hydrogen or fluorine,

R<sup>3</sup> and R<sup>4</sup> represent hydrogen,

R<sup>5</sup> represents hydrogen,

R<sup>6</sup> represents a radical selected from the group consisting of:

(C<sub>1</sub>-C<sub>6</sub>) alkyl which is substituted by amino, hydroxyl, (C<sub>1</sub>-C<sub>6</sub>) alkylamino, eyelohexylamino or piperidinyl,

where alkylamino or cyclohexylamino for their part may be substituted by hydroxyl or phenyl,

Docket No.: BHC 031069 PCT-US

(C<sub>1</sub>-C<sub>6</sub>) alkoxy which may be substituted by amino or (C<sub>1</sub>-C<sub>6</sub>) alkylamino,

eyelopentyl, piperazinyl, piperidinyl, pyrrolidinyl, piperidinyloxy or pyrrolidinyloxy,

where cyclopentyl, piperazinyl, piperidinyl, pyrrolidinyl, piperidinyloxy or pyrrolidinyloxy may be substituted by amino, hydroxyl,  $(C_4 - C_2)$  alkyl or benzyloxy,

and phenyl or thienyl,

where phenyl or thienyl may be substituted by  $(C_1 - C_2)$  alkyl which for its part may be substituted by amino or  $(C_1 - C_6)$  alkylamino,

and its salts, hydrates, hydrates of the salts and solvates.

4. (Withdrawn) Process for preparing compounds of the formula (I) as defined in Claim 1, characterized in that either

## [A] compounds of the formula

$$A \xrightarrow{Y} \xrightarrow{R^1} R^4$$

$$R^2 \xrightarrow{N} R^5$$
(II),

in which

A, Y, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined in Claim 1

are reacted with compounds of the formula

$$X^1$$
 $R^6$  (III) or  $X^1$ 
 $R^{6a}$  (IIIa),

in which

R<sup>6</sup> is as defined in Claim 1,

R<sup>6a</sup> corresponds to a radical R<sup>6</sup> as defined above which, however, contains, instead of a secondary or tertiary amino group, a chlorine substituent or, instead of a free amino group, a nitro group or a protected amino group, and

X<sup>1</sup> represents halogen, preferably chlorine or bromine, or hydroxyl,

and, in the case of the reaction with compounds (IIIa) in the radical R<sup>6a</sup>, the chlorine substituent is subsequently substituted by an amine, the nitro group is hydrogenated to give the corresponding amino group or the protective group is cleaved off to release the corresponding free amino group

# [B] compounds of the formula

$$A \xrightarrow{P} R^{1}$$

$$R^{2} \xrightarrow{R^{3}} N \xrightarrow{R^{5}} (IV),$$

in which

A, Y, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined in Claim 1

are reacted with compounds of the formula

$$H_2N-R^8$$
 (V)

in which

R<sup>8</sup> is as defined in Claim 1.

- 5. (Canceled)
- 6. (Withdrawn) Use of a compound as defined in any of Claims 1 to 3 for preparing medicaments for the treatment and/or prophylaxis of cardiovascular disorders.
- 7. (Withdrawn) Use of a compound as defined in any of Claims 1 to 3 for preparing medicaments for the treatment and/or prophylaxis of erectile dysfunction.
- 8. (Withdrawn) Method for the treatment and/or prophylaxis of cardiovascular disorders comprising the use of a cardiovascularly effective amount of a compound as defined in any of Claims 1 to 3.
- 9. (Withdrawn) Medicament A pharmaceutical composition comprising a compound as defined in any of Claims 1 to 3 in combination with a further active compound.
- 10. (Currently amended) Medicament A pharmaceutical composition comprising a compound as defined in any of Claims 1 to 3 in combination with an inert non-toxic pharmaceutically suitable auxiliary.

- 11. (Currently amended) Medicament The pharmaceutical composition according to Claim 9 or 10 for the treatment and/or prophylaxis of cardiovascular disorders.
- 12. (Currently amended) Medicament The pharmaceutical composition according to Claim 9 or 10 for the treatment and/or prophylaxis of erectile dysfunction.
- 13. (New) The pharmaceutical composition according to Claim 10 for the treatment and/or prophylaxis of cardiovascular disorders.
- 14. (New) The pharmaceutical composition according to Claim 10 for the treatment and/or prophylaxis of erectile dysfunction.